Verrica Pharmaceuticals Inc
F:1NE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Verrica Pharmaceuticals Inc
F:1NE
|
US |
|
RedTape
BSE:543957
|
IN |
|
Controladora Vuela Compania de Aviacion SAB de CV
BMV:VOLARA
|
MX |
|
S
|
Societe Generale SA
SWB:SGE
|
FR |
Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals makes prescription treatments for skin diseases, with a focus on office-based dermatology care. Its main product is YCANTH, a cantharidin-based drug that doctors apply to treat molluscum contagiosum, a contagious skin condition. The company’s work is centered on turning a simple skin-directed therapy into a regulated drug that clinicians can use in the office. Verrica sells its product to healthcare providers and health systems, and the patients are the people being treated for skin lesions. The company makes money mainly by selling its approved dermatology product and, when relevant, by licensing or developing follow-on uses for its skin-treatment technology. Because the treatment is applied by medical professionals rather than taken at home, the company sits in a niche part of the dermatology market that depends on physician adoption and prescription access. What makes Verrica different is its narrow focus on dermatologist-administered therapies for specific skin conditions. Instead of chasing a broad drug portfolio, it concentrates on a single specialty area where a targeted treatment can replace older, less controlled approaches. That makes its business easy to understand: develop and commercialize office-based skin medicines that doctors can prescribe and apply directly.
Verrica Pharmaceuticals makes prescription treatments for skin diseases, with a focus on office-based dermatology care. Its main product is YCANTH, a cantharidin-based drug that doctors apply to treat molluscum contagiosum, a contagious skin condition. The company’s work is centered on turning a simple skin-directed therapy into a regulated drug that clinicians can use in the office.
Verrica sells its product to healthcare providers and health systems, and the patients are the people being treated for skin lesions. The company makes money mainly by selling its approved dermatology product and, when relevant, by licensing or developing follow-on uses for its skin-treatment technology. Because the treatment is applied by medical professionals rather than taken at home, the company sits in a niche part of the dermatology market that depends on physician adoption and prescription access.
What makes Verrica different is its narrow focus on dermatologist-administered therapies for specific skin conditions. Instead of chasing a broad drug portfolio, it concentrates on a single specialty area where a targeted treatment can replace older, less controlled approaches. That makes its business easy to understand: develop and commercialize office-based skin medicines that doctors can prescribe and apply directly.
YCANTH growth: Verrica said demand accelerated in the first quarter, with U.S. YCANTH revenue up 25.4% year over year and dispensed applicator units up 51.3%. Management also said April demand was even stronger than March’s record level.
Pipeline progress: The company said its common warts Phase III program is advancing, with more than 50% enrollment reached in the first trial and a second trial still targeted for mid-2026. VP-315 for basal cell carcinoma is also moving toward Phase III planning.
Cash runway: Verrica ended the quarter with $20.6 million in cash and said that is expected to fund operations into the first quarter of 2027.
Commercial execution: Management pointed to YCANTH Rx, co-pay support, and a sales force optimization review as key tools to broaden access and drive adoption, especially as spring and summer seasonality may help demand.
Europe and Japan: YCANTH launched in Japan through partner Torii in February, and Verrica said it is progressing toward a European filing with no further Phase III studies required for EU approval.
